SPARC

Sun Pharma Advanced Research Company Share Price

 

 

Invest in Sun Pharma Advanced Research Company with 2.64X leverage

Invest with MTF

Performance

  • Low
  • ₹134
  • High
  • ₹136
  • 52 Week Low
  • ₹109
  • 52 Week High
  • ₹208
  • Open Price₹134
  • Previous Close₹134
  • Volume834,681

Investment Returns

  • Over 1 Month + 1.57%
  • Over 3 Month -1.17%
  • Over 6 Month -13.66%
  • Over 1 Year -32.63%

Smart Investing Starts Here Start SIP with Sun Pharma Advanced Research Company for Steady Growth!

Invest Now

Sun Pharma Advanced Research Company Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -16.5
  • PEG Ratio
  • -0.5
  • Market Cap Cr
  • 4,401
  • P/B Ratio
  • -12.8
  • Average True Range
  • 7.11
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.3
  • RSI
  • 47.99
  • MFI
  • 48.46

Sun Pharma Advanced Research Company Financials

Sun Pharma Advanced Research Company Technicals

EMA & SMA

Current Price
₹135.61
+ 1.6 (1.19%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹137.62
  • 50 Day
  • ₹137.67
  • 100 Day
  • ₹140.50
  • 200 Day
  • ₹151.08

Resistance and Support

135.32 Pivot Speed
  • R3 138.69
  • R2 137.47
  • R1 136.54
  • S1 134.39
  • S2 133.17
  • S3 132.24

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sun Pharma Advanced Research Company Ltd. (SPARC) focuses on developing innovative pharmaceutical products, including novel drug delivery systems and new chemical entities. It drives research in therapeutic areas like oncology, dermatology, and neurology to address unmet medical needs.

Sun Pharma Advd.Resh. has an operating revenue of Rs. 59.60 Cr. on a trailing 12-month basis. An annual revenue de-growth of -30% needs improvement, Pre-tax margin of -478% needs improvement, NULL The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 37 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sun Pharma Advanced Research Company Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-08-04 Quarterly Results
2025-05-19 Audited Results
2025-02-10 Quarterly Results
2024-11-04 Quarterly Results

Sun Pharma Advanced Research Company F&O

Sun Pharma Advanced Research Company Shareholding Pattern

65.67%
1.01%
0%
1.76%
0%
18.94%
12.62%

About Sun Pharma Advanced Research Company

  • NSE Symbol
  • SPARC
  • BSE Symbol
  • 532872
  • ISIN
  • INE232I01014

Similar Stocks to Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company FAQs

Sun Pharma Advanced Research Company share price is ₹135 As on 26 December, 2025 | 01:21

The Market Cap of Sun Pharma Advanced Research Company is ₹4400.8 Cr As on 26 December, 2025 | 01:21

The P/E ratio of Sun Pharma Advanced Research Company is -16.5 As on 26 December, 2025 | 01:21

The PB ratio of Sun Pharma Advanced Research Company is -12.8 As on 26 December, 2025 | 01:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23